scispace - formally typeset
Journal ArticleDOI

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families

Reads0
Chats0
TLDR
It is concluded that when index patients are treated concurrently, rimantadine is ineffective in protecting household members from influenza A infection and rapid selection and apparent transmission of drug-resistant influenza A viruses can occur.
Abstract
To determine whether rimantadine can protect family members from acquiring influenza A viral illness and to assess the possible selection of drug-resistant strains of virus, we conducted a randomized, double-blind, placebo-controlled study in three communities during two influenza seasons. When influenza A occurred in a family, the members (including the index patient) were given either rimantadine (adult oral dose, 200 mg per day) or placebo for 10 days. The presence of illness was monitored by daily recording of symptoms and temperature measurements; infection was determined by isolation of the virus and by serologic studies. Among households with documented influenza A infections, symptomatic illness occurred in one or more contacts in 10 of 28 families treated with rimantadine and in 10 of 29 families treated with placebo. Asymptomatic secondary influenza A infections were found in five families assigned to receive rimantadine and in four families assigned to receive placebo. Rimantadine-resi...

read more

Citations
More filters
Journal Article

Prevention and control of influenza : recommendations of the Advisory Committee on Immunization Practices (ACIP)

TL;DR: This report updates the 2000 recommendations by the Advisory Committee on Immunization Practices on the use of influenza vaccine and antiviral agents with new or updated information regarding the cost-effectiveness of influenza vaccination and the 2001-2002 trivalent vaccine virus strains.
Journal ArticleDOI

Rational design of potent sialidase-based inhibitors of influenza virus replication.

TL;DR: Two potent inhibitors based on the crystal structure of influenza virus sialidase have been designed and provide an example of the power of rational, computer-assisted drug design, indicating significant progress in the development of a new therapeutic or prophylactic treatment for influenza infection.
Journal Article

Guidelines for Preventing Health-Care-- Associated Pneumonia, 2003 Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee

TL;DR: The new guidelines are designed to reduce the incidence of pneumonia and other severe, acute lower respiratory tract infections in acute-care hospitals and in other health-care settings (e.g., ambulatory and longterm care institutions) and other facilities where health care is provided.
Journal ArticleDOI

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.

TL;DR: The design, synthesis, and in vitro evaluation of the novel carbocycles as transition-state-based inhibitors of influenza neuraminidase (NA) are described and the presence of a large hydrophobic pocket in the region corresponding to the glycerol subsite of sialic acid is revealed.
Journal ArticleDOI

Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza

TL;DR: The data suggest that oral oseltamivir treatment reduces the duration and severity of acute influenza in healthy adults and may decrease the incidence of secondary complications.
References
More filters
Journal ArticleDOI

DNA sequencing with chain-terminating inhibitors

TL;DR: A new method for determining nucleotide sequences in DNA is described, which makes use of the 2',3'-dideoxy and arabinon nucleoside analogues of the normal deoxynucleoside triphosphates, which act as specific chain-terminating inhibitors of DNA polymerase.
Journal ArticleDOI

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection

TL;DR: Rimantadine appears to be the drug of choice for the prophylaxis of influenza A, as compared with placebo in a placebo-controlled, double-blind, randomized trial.
Journal ArticleDOI

Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.

TL;DR: Analysis of reassortant viruses generated with a resistant clinical isolate and the susceptible influenza A/Singapore/57 (H2N2) virus indicated that RNA segment 7 coding for matrix and M2 proteins conferred the resistant phenotype.
Journal ArticleDOI

Molecular basis of resistance of influenza A viruses to amantadine.

TL;DR: Mutations which confer resistance to amantadine are restricted to four amino acids within a hydrophobic sequence of M2 indicating that the primary target of drug action is the membrane-associated portion of this molecule.
Related Papers (5)